Abstract: The claimed invention provides therapeutic as well as protective measures against colorectal cancer by utilizing genetically modified gut bacteria (101) in conjunction with an optimized diet high in cruciferous vegetable intake. According to the claimed system and method, engineered gut bacteria maximize the therapeutic value of the cruciferous vegetable diet to eradicate, offset or prophylactically prevent the onset of colorectal cancer. In the claimed invention gut bacteria Escherichia coli bind specifically to the heparan sulphate proteoglycan on colorectal cancer cells to secrete the enzyme myrosinase to transform host-ingested glucosinolates which are natural components of cruciferous vegetables to sulphoraphane, an organic small molecule with known anti-cancer activity.

Abstract: The present invention relates to a composition comprising or consisting of two or more bacteria strains, formulated for the prophylaxis or treatment of intestinal barrier dysfunction and/or heat stress in a subject. More particularly, the composition comprises two or more of Lactobacillus reuteri MM2-3, Lactobacillus plantarum WCSF1, Streptococcus thermophilus B of R and Escherichia coli Nissle 1917. The present invention also includes uses of the invention to treat conditions such as inflammatory bowel disease (IBD) and heat stress.

Abstract: The present invention relates to the metabolic engineering of a microbial host for the synthesis of value-added products from oil palm empty fruit brunches (OPEFBs). In one embodiment, the genetically engineered microorganism is Escherichia coli comprising a metabolic pathway consisting of 9 enzymes (11 genes) to utilize depolymerized lignin, namely vanillin, p-coumaric acid, p-hydroxybenzaldehyde, vanillic acid, p-hydroxybenzoic acid and ferulic acid, to produce ?-ketoadipic acid, which can be subsequently converted into commercially important derivatives such as adipic acid and levulinic acid. The enzymes are feruloyl-CoA synthetase (fcs), enoyl-CoA hydratase (ech), vanillin dehydrogenase (vdh), vanillate O-demethylase (vanA; vanA and vanB), p-hydroxy benzoate hydroxylase (pobA), protocatechuate 3,4-dioxygenase {pcaGH; pcaG and pcaH), 3-carboxy-cis, cis-muconate cycloisomerase (pcaB), 4-carboxymuconolactone decarboxylase (pcaC), and ?-ketoadipate enol-lactone hydrolase (pcaD).

Abstract: The present invention provides for a method to increase the free lipoic acid production in an isolated genetically engineered bacteria or yeast cell. The method involves culturing in a cysteine supplemented culture medium the engineered bacteria or yeast that is transformed with a recombinant expression vector encoding polynucleotide molecules that results in the overexpression of the following genes that are linked to at least one promoter: (1) substrate protein (e.g. Gcv3p); (2) octanoyltransferase or lipoyl synthase; (3) cofactor S-adenosyl methionine synthase; and (4) lipoamidase. The invention also relates to the engineered bacteria or yeast cell thereof.

Abstract: The present invention relates to methods of metabolic engineering bacteria cells to produce bile salt hydrolase to inhibit the germination of C. difficile endospores and colonisation within the human gastrointestinal tract. The bile salt hydrolase is operably linked to a sialic acid-inducible promoter, pNanA, of which pNanA is in turn controlled by the repressor nanR. The recombinant bacteria expressing the bile salt hydrolase can be a probiotic strain to be used for prophylaxis or treatment of C. difficile infection.

Abstract: The claimed invention provides therapeutic as well as protective measures against colorectal cancer by utilizing genetically modified gut bacteria (101) in conjunction with an optimized diet high in cruciferous vegetable intake. According to the claimed system and method, engineered gut bacteria maximize the therapeutic value of the cruciferous vegetable diet to eradicate, offset or prophylactically prevent the onset of colorectal cancer. In the claimed invention gut bacteria Escherichia coli bind specifically to the heparan sulphate proteoglycan on colorectal cancer cells to secrete the enzyme myrosinase to transform host-ingested glucosinolates which are natural components of cruciferous vegetables to sulphoraphane, an organic small molecule with known anti-cancer activity.

Abstract: The claimed invention provides therapeutic as well as protective measures against colorectal cancer by utilizing genetically modified gut bacteria (101) in conjunction with an optimized diet high in cruciferous vegetable intake. According to the claimed system and method, engineered gut bacteria maximize the therapeutic value of the cruciferous vegetable diet to eradicate, offset or prophylactically prevent the onset of colorectal cancer. In the claimed invention gut bacteria Escherichia coli bind specifically to the heparan sulphate proteoglycan on colorectal cancer cells to secrete the enzyme myrosinase to transform host-ingested glucosinolates which are natural components of cruciferous vegetables to sulphoraphane, an organic small molecule with known anti-cancer activity.

Abstract: An Expression system; isolated nucleic acid molecule or host cell comprising: (i) A first gene encoding for a first enzyme linked to a first promoter, wherein the first promoter is a time delay promoter; (ii) A second gene encoding for a second enzyme capable of using the product generated by the first enzyme as a substrate, wherein the second gene is operably linked to a second promoter, wherein the second promoter is inducible by the product generated by the first enzyme; (iii) Optionally, a third gene encoding a transcription factor that represses expression of the second gene in the absence of the product generated by the first enzyme, wherein the third gene is operably linked to a third promoter that regulates expression of the third gene; and its use in producing a product such as hydroxybenzaldehyde.

Abstract: The claimed invention provides therapeutic as well as protective measures against colorectal cancer by utilizing genetically modified gut bacteria (101) in conjunction with an optimized diet high in cruciferous vegetable intake. According to the claimed system and method, engineered gut bacteria maximize the therapeutic value of the cruciferous vegetable diet to eradicate, offset or prophylactically prevent the onset of colorectal cancer. In the claimed invention gut bacteria Escherichia coli bind specifically to the heparan sulphate proteoglycan on colorectal cancer cells to secrete the enzyme myrosinase to transform host-ingested glucosinolates which are natural components of cruciferous vegetables to sulphoraphane, an organic small molecule with known anti-cancer activity.

Abstract: The present invention relates to a nucleic acid molecule that comprises at least one synthetic GAL1 core promoter containing one or more ligand responsive operator sequences, preferably one or more FadR operator sites; at least one upstream enhancer element (UEE); and at least one nucleotide sequence encoding for one or more genes of interest; wherein the at least one synthetic GAL1 core promoter is operably linked to the at least one nucleotide sequence encoding for one or more genes of interest and the at least one UEE is operably linked to the at least one synthetic GAL1 core promoter. Also encompassed are expression systems and recombinant cells that include these nucleic acid molecules and methods that use these nucleic acid molecules, expression systems or cells.

Abstract: Modified Saccharomyces cerevisiae yeast that produce terminal alkenes are described. The modification of the Saccharomyces cerevisiae yeast includes insertion of at least one heterologous fatty acid decarboxylase gene, deletion of FAA1 and FAA4, overexpression of HEM3, and triple-deletion of CTT1, CTA1 and CCP1. Methods of producing terminal alkenes by culturing and fermenting the modified Saccharomyces cerevisiae yeast and optionally harvesting the terminal alkenes are also described. Mixtures of terminal alkenes produced by the modified Saccharomyces cerevisiae yeast, and methods of metabolically engineering a yeast for optimizing overexpression of one or more alkenes are also described.

Abstract: The present invention relates to an expression system or a recombinant cell comprising one or more nucleic acid constructs, wherein the one or more nucleic acid constructs comprise: (i) a first gene encoding for one or more protein(s) that activate a quorum sensing system; and (ii) a second gene encoding for one or more lytic protein(s) capable of forming a lesion in a host cell's membrane; wherein the first gene is under control of a first promoter and the second gene is under control of a second promoter, wherein the first promoter controlling the first gene is a carbon starvation-induced promoter and the second promoter is a quorum sensing system promoter induced by the quorum sensing system activated by one or more protein(s) encoded by the first gene as well as recombinant cells hosting such an expression system. Further encompassed is the use of the expression systems and cells of the invention for the expression of gene products of interest and the respective methods of use.

Abstract: Recombinant cell expressing at least one heterologous alkane exporter protein comprising an ATP binding cassette (ABC), wherein the ABC comprises of an amino acid consensus sequence as set forth in SEQ ID No. 1. The use and method of producing or increasing resistance to biofuels with the same.

Abstract: Modified Saccharomyces cerevisiae yeast that produce terminal alkenes are described. The modification of the Saccharomyces cerevisiae yeast includes insertion of at least one heterologous fatty acid decarboxylase gene, deletion of FAA1 and FAA4, overexpression of HEM3, and triple-deletion of CTT1, CTA1 and CCP1. Methods of producing terminal alkenes by culturing and fermenting the modified Saccharomyces cerevisiae yeast and optionally harvesting the terminal alkenes are also described. Mixtures of terminal alkenes produced by the modified Saccharomyces cerevisiae yeast, and methods of metabolically engineering a yeast for optimizing overexpression of one or more alkenes are also described.

Abstract: The present invention relates to an isolated nucleic acid molecule comprising (a) a first nucleotide sequence encoding a protein that detects the presence, amount or both of a pathogenic microorganism by forming a complex with a quorum sensing molecule produced by said pathogenic microorganism, (b) one or more second nucleotide sequence said one or more second nucleotide sequence being under control of a promoter that is induced by the complex of the protein encoded by the first nucleotide sequence and the quorum sensing molecule produced by said pathogenic microorganism and encoding (i) an antimicrobial peptide, wherein the antimicrobial peptide is effective against the pathogenic microorganism detected by the protein encoded by the first nucleotide sequence; and/or an antibiofilm enzyme wherein the antibiofilm enzyme is effective against the pathogenic microorganism detected by the protein encoded by the first nucleotide sequence; and (c) optionally a third nucleotide sequence encoding a protein that contro

Abstract: The present invention relates to a nucleic acid molecule that comprises at least one synthetic GAL1 core promoter containing one or more ligand responsive operator sequences, preferably one or more FadR operator sites; at least one upstream enhancer element (UEE); and at least one nucleotide sequence encoding for one or more genes of interest; wherein the at least one synthetic GAL1 core promoter is operably linked to the at least one nucleotide sequence encoding for one or more genes of interest and the at least one UEE is operably linked to the at least one synthetic GAL1 core promoter. Also encompassed are expression systems and recombinant cells that include these nucleic acid molecules and methods that use these nucleic acid molecules, expression systems or cells.

Abstract: An object of the present invention is to provide a polymerizable composition capable of providing antimicrobial properties to ophthalmic and medical devices relatively inexpensively with ease, and an antimicrobial composition obtained by polymerizing the polymerizable composition. A polymerizable composition for ophthalmic or medical use comprising an epsilon-polylysine having (meth)acryloyl group is provided. The content of the epsilon-polylysine having (meth)acryloyl group in the polymerizable composition is preferably about 0.1 to 99% by weight, based on the whole amount of the composition. A coating agent for ophthalmic or medical use comprising the above polymerizable composition, an antimicrobial composition for ophthalmic or medical use obtained by polymerizing the above polymerizable composition, an ophthalmic or medical device comprising the antimicrobial composition, and a contact lens comprising the antimicrobial composition are also provided.

Abstract: The present invention relates to an expression system or a recombinant cell comprising one or more nucleic acid constructs, wherein the one or more nucleic acid constructs comprise: (i) a first gene encoding for one or more protein(s) that activate a quorum sensing system; and (ii) a second gene encoding for one or more lytic protein(s) capable of forming a lesion in a host cell's membrane; wherein the first gene is under control of a first promoter and the second gene is under control of a second promoter, wherein the first promoter controlling the first gene is a carbon starvation-induced promoter and the second promoter is a quorum sensing system promoter induced by the quorum sensing system activated by one or more protein(s) encoded by the first gene as well as recombinant cells hosting such an expression system. Further encompassed is the use of the expression systems and cells of the invention for the expression of gene products of interest and the respective methods of use.

Abstract: The present invention relates to an isolated nucleic acid molecule comprising (a) a first nucleotide sequence encoding a protein that detects the presence, amount or both of a pathogenic microorganism by forming a complex with a quorum sensing molecule produced by said pathogenic microorganism, (b) one or more second nucleotide sequence said one or more second nucleotide sequence being under control of a promoter that is induced by the complex of the protein encoded by the first nucleotide sequence and the quorum sensing molecule produced by said pathogenic microorganism and encoding (i) an antimicrobial peptide, wherein the antimicrobial peptide is effective against the pathogenic microorganism detected by the protein encoded by the first nucleotide sequence; and/or an antibiofilm enzyme wherein the antibiofilm enzyme is effective against the pathogenic microorganism detected by the protein encoded by the first nucleotide sequence; and (c) optionally a third nucleotide sequence encoding a protein that contro

Abstract: Recombinant cell expressing at least one heterologous alkane exporter protein comprising an ATP binding cassette (ABC), wherein the ABC comprises of an amino acid consensus sequence as set forth in SEQ ID No. 1. The use and method of producing or increasing resistance to biofuels with the same.